Maraviroc-intensified ART may have anti neuroinflammatory properties which could result in cognitive benefits. However intensified ART may be associated with increased neurotoxicity.
Therapy naïve, neurologically asymptomatic, HIV-positive patients were randomly allocated on a 1:1 basis to a standard boosted-protease-inhibitor (bPI) ART regimen (Arm1; tenofovir-emtricitabine plus atazanavir/r) or a maraviroc 150mg once daily intensified bPI regimen (Arm2: abacavir-lamivudine plus darunavir/r/maraviroc). A detailed assessment of 11 cognitive function (CF) tests was undertaken at baseline and after 12, 24, 36 and 48 weeks and cerebral metabolites measured using proton magnetic resonance spectroscopy in the right frontal white matter (FWM) at baseline. Mean and proportional changes in CF, changes in individual domains between treatment arms and factors associated with changes in CF were assessed.
Of 60 subjects randomised (30 Arm1 and 30 Arm2), 58 were male and 44 of white ethnicity. Treatment groups had similar disease characteristics including overall mean (SD) baseline CD4+ count 425 (246) and 434 (229) cells/uL and plasma HIV RNA (IQR) 44K (16 to 69K) and 53K (27 to 81K) copies/mL in arms1 and 2, respectively. At week 48 plasma HIV RNA was <200 copies/mL in all and mean (SD) CD4+ count was 586 (209) and 611 (249) cells/uL in arms1 and 2, respectively.
CF improved over 48 weeks (mean change z-score 0.19 Arm1 and 0.24 Arm2, figure). No statistically significant differences in changes in individual domains or overall CF were observed between study treatment arms however proportional change in overall CF from baseline was numerically greater in arm1. In a multivariate model, greater improvements in overall CF was associated with greater baseline CF performance (coef 0.82, p<0.005) and higher FWM neuronal metabolites (n-acetly aspartate/creatine ratio, coef 0.51, p<0.05).
Maraviroc-intensified ART had no demonstrable benefit on CF. In subjects with higher baseline cerebral function markers (higher CF performance and neuronal metabolites), greater improvements in CF was observed. We hypothesise a greater reversibility of underlying disease processes may occur in such individuals.